MiMedx Group, Inc (NASDAQ:MDXG) Given Consensus Recommendation of “Moderate Buy” by Brokerages

MiMedx Group, Inc (NASDAQ:MDXG) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $9.50.

Several analysts have issued reports on MDXG shares. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Lake Street Capital dropped their price target on MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. UBS Group set a $10.00 price target on MiMedx Group in a report on Monday. Wall Street Zen upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 2nd. Finally, Mizuho dropped their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th.

Institutional Investors Weigh In On MiMedx Group

Institutional investors have recently made changes to their positions in the company. CWM LLC grew its position in shares of MiMedx Group by 63.8% in the second quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after purchasing an additional 1,892 shares during the last quarter. Legato Capital Management LLC grew its holdings in MiMedx Group by 18.5% in the 3rd quarter. Legato Capital Management LLC now owns 17,341 shares of the company’s stock valued at $121,000 after buying an additional 2,708 shares in the last quarter. HighMark Wealth Management LLC grew its holdings in MiMedx Group by 5.4% in the 3rd quarter. HighMark Wealth Management LLC now owns 55,878 shares of the company’s stock valued at $390,000 after buying an additional 2,878 shares in the last quarter. SkyView Investment Advisors LLC increased its position in MiMedx Group by 3.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after buying an additional 3,032 shares during the period. Finally, Rafferty Asset Management LLC lifted its holdings in shares of MiMedx Group by 4.6% during the fourth quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock worth $469,000 after buying an additional 3,064 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Down 0.6%

Shares of MDXG stock opened at $5.17 on Monday. MiMedx Group has a 52-week low of $4.89 and a 52-week high of $8.46. The stock has a market cap of $765.68 million, a price-to-earnings ratio of 19.15 and a beta of 1.59. The firm’s 50-day moving average is $5.89 and its 200-day moving average is $6.64. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.